Literature DB >> 24251708

Non-alcoholic fatty liver disease: factors associated with its presence and onset.

Teruki Miyake1, Teru Kumagi, Shinya Furukawa, Yoshio Tokumoto, Masashi Hirooka, Masanori Abe, Yoichi Hiasa, Bunzo Matsuura, Morikazu Onji.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) may progress to cirrhosis, liver failure, and complicated hepatocellular carcinoma. In addition, NAFLD is a risk factor for the development of other serious diseases, such as diabetes or cardiovascular disease. Therefore, the detection of early-stage NAFLD is important. Many studies have described the factors that predict the presence of NAFLD and its onset, and several markers have been identified. These markers have enabled the identification of high-risk patients and have improved routine medical practice. To prevent advanced disease, clinicians need to have simple markers that predict the onset of NAFLD so that interventions can be started at much earlier stages of disease. This review summarizes the current state of knowledge regarding independent factors, as reported in large studies, that predict the presence of NAFLD and its onset, especially markers that can be used in daily medical practice, such as physical measurements and blood tests.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  blood tests; non-alcoholic fatty liver disease; physical measurements; predictive factors; risk factors

Mesh:

Substances:

Year:  2013        PMID: 24251708     DOI: 10.1111/jgh.12251

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  12 in total

1.  Short sleep duration reduces the risk of nonalcoholic fatty liver disease onset in men: a community-based longitudinal cohort study.

Authors:  Teruki Miyake; Teru Kumagi; Shinya Furukawa; Masashi Hirooka; Keitarou Kawasaki; Mitsuhito Koizumi; Yasuhiko Todo; Shin Yamamoto; Yoshio Tokumoto; Yoshio Ikeda; Masanori Abe; Kohichiro Kitai; Bunzo Matsuura; Yoichi Hiasa
Journal:  J Gastroenterol       Date:  2014-08-13       Impact factor: 7.527

Review 2.  Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty liver.

Authors:  Jinyao Liu
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

3.  Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study.

Authors:  Xiaoping Tang; Yanyan Shi; Juan Du; Keming Hu; Tingting Zhou; Lan Chen; Yanming Zhang; Fujun Li; Huier Zhang; Roman Liebe; Christoph Meyer; Steven Dooley; Zhongwei Zhu; Hong-Lei Weng; Jinzhu Jia; Tong Huang
Journal:  BMJ Open       Date:  2022-06-27       Impact factor: 3.006

4.  Significance of exercise in nonalcoholic fatty liver disease in men: a community-based large cross-sectional study.

Authors:  Teruki Miyake; Teru Kumagi; Masashi Hirooka; Shinya Furukawa; Keitarou Kawasaki; Mitsuhito Koizumi; Yasuhiko Todo; Shin Yamamoto; Hiroaki Nunoi; Yoshio Tokumoto; Yoshio Ikeda; Masanori Abe; Kohichiro Kitai; Bunzo Matsuura; Yoichi Hiasa
Journal:  J Gastroenterol       Date:  2014-04-21       Impact factor: 7.527

5.  Identification of novel clinical factors associated with hepatic fat accumulation in extreme obesity.

Authors:  Glenn S Gerhard; Peter Benotti; G Craig Wood; Xin Chu; George Argyropoulos; Anthony Petrick; William E Strodel; Jon D Gabrielsen; Anna Ibele; Christopher D Still; Christopher Kingsley; Johanna DiStefano
Journal:  J Obes       Date:  2014-12-24

6.  Low Serum Lysosomal Acid Lipase Activity Correlates with Advanced Liver Disease.

Authors:  Eyal Shteyer; Rivka Villenchik; Mahmud Mahamid; Nidaa Nator; Rifaat Safadi
Journal:  Int J Mol Sci       Date:  2016-02-27       Impact factor: 5.923

7.  A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains.

Authors:  G Craig Wood; Xin Chu; George Argyropoulos; Peter Benotti; David Rolston; Tooraj Mirshahi; Anthony Petrick; John Gabrielson; David J Carey; Johanna K DiStefano; Christopher D Still; Glenn S Gerhard
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

8.  Recommendations for the management of non-alcoholic fatty liver disease (NAFLD).

Authors:  Krzysztof Tomasiewicz; Robert Flisiak; Waldemar Halota; Jerzy Jaroszewicz; Dariusz Lebensztejn; Wojciech Lisik; Piotr Małkowski; Małgorzata Pawłowska; Anna Piekarska; Krzysztof Simon; Olga Tronina
Journal:  Clin Exp Hepatol       Date:  2018-09-10

9.  Relationship Between Serum Uric Acid Levels and Nonalcoholic Fatty Liver Disease in Non-Obese Patients.

Authors:  Alihan Oral; Tolga Sahin; Fatih Turker; Erdem Kocak
Journal:  Medicina (Kaunas)       Date:  2019-09-17       Impact factor: 2.430

10.  Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome.

Authors:  Hande Erman; Engin Beydogan; Seher Irem Cetin; Banu Boyuk
Journal:  Mediators Inflamm       Date:  2020-04-01       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.